GURUFOCUS.COM » STOCK LIST » Basic Materials » Metals & Mining » Palisades Goldcorp Ltd (TSXV:PALI) » Definitions » Other Financing

Switch to:

Palisades Goldcorp (TSXV:PALI) Other Financing : C$0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Palisades Goldcorp Other Financing?

Palisades Goldcorp's Other Financing for the three months ended in Sep. 2024 was C$0.00 Mil.

Palisades Goldcorp's Other Financing for the trailing twelve months (TTM) ended in Sep. 2024 was C$0.00 Mil.

Palisades Goldcorp Other Financing Historical Data

The historical data trend for Palisades Goldcorp's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palisades Goldcorp Other Financing Chart

Palisades Goldcorp Annual Data

Trend

Dec21

Dec22

Dec23

Other Financing

44.79

-

-

Palisades Goldcorp Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Financing	Get a 7-Day Free Trial							-	-	-	-	-

Palisades Goldcorp Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Palisades Goldcorp Other Financing Related Terms

Thank you for viewing the detailed overview of Palisades Goldcorp's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Palisades Goldcorp Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Metals & Mining » Palisades Goldcorp Ltd (TSXV:PALI) » Definitions » Other Financing

Comparable Companies

Traded in Other Exchanges

PLGDF:USA

Address

WeWork c/o Palisades Goldcorp Ltd.,1600 - 595 Burrard Street, Vancouver, BC, CAN, V7X 1L4

Website

https://www.palisades.ca

Palisades Goldcorp Ltd is a Canadian resource merchant bank. The company is engaged in investing in resource properties.

Executives

Michael A Parker

10% Security Holder

Palisades Goldcorp Headlines

From GuruFocus

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

By Marketwired • 12-13-2024

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

By Marketwired • 10-31-2024

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

By Marketwired • 12-12-2024

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)�

By Marketwired • 02-20-2025

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

By Marketwired • 10-10-2024

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

By Marketwired • 11-12-2024

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

By Marketwired • 11-07-2024

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

By Marketwired • 12-03-2024

Palisade Bio Participates in Virtual Investor �What This Means� Segment

By Marketwired • 03-04-2025

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification

By Marketwired • 09-05-2024

Home About Jobs Site Map Term of Use Privacy Policy Mobile App Referral Program Partner Program FAQ Contact Us 中文 All-In-One Screener
Stock List Guru List Insider List Insider Trade Economic Indicators Industry Data DCF Calculator Discussion Board Plans Excel Add-In Google Sheets Add-on
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.